Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): An FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 452-457

  Penel, N ^a,b   Le Cesne, A ^c   Bui, B N ^d   Perol, D ^e   Brain, E G ^f   Ray Coquard, I ^e   Guillemet, C ^g   Chevreau, C ^h   Cupissol, D ⁱ   Chabaud, S ^e   Jimenez, M ^j   Duffaud, F ^k   Piperno Neumann, S ^l   Mignot, L ^m   Blay, J Y ⁿ  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUT BERGONIÉ   (France)

^e CENTRE LÉON BÉRARD   (France)

^f Center René Huguenin   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ CENTRE VAL D AURELLE   (France)

^j FNCLCC   (France)

^k TIMONE HOSPITAL   (France)

^l INSTITUT CURIE   (France)

^m FOCH HOSPITAL   (France)

ⁿ EDOUARD HERRIOT HOSPITAL   (France)

more..

Author keywords

Aggressive fibromatosis; Desmoid tumor; Imatinib; Phase II trial

Indexed keywords

IMATINIB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DESMOID TUMOR; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROMATOSIS; FOLLOW UP; HUMAN; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RHABDOMYOLYSIS; SURVIVAL RATE; VOMITING;

EID: 79251560032     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq341     Document Type: Article

References (26)

1. Biermann JS. Desmoid tumours. Curr Treat Options Oncol 2000; 1: 262-266.
2. Penel N, Grosjean J, Robin YM et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma 2008; 2008: 459386.
3. Gardner EJ. Follow up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas, and epidermal cysts. Am J Hum Genet 1962; 14: 376-390.
4. Posner MC, Shiu MH, Newsome JL et al. The desmoid tumor: not a benign disease. Arch Surg 1989; 124: 191-196.
5. Shapek SX, Ferguson WS, Granowetter L et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial. J Clin Oncol 2007; 25: 501-506.
6. Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986; [151:] 230-237.
7. Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extraabdominal aggressive fibromatosis: a series of patients surgically treated by a single institution. J Clin Oncol 2003; 21: 1390-1397.
8. Gega M, Yanagi H, Yoshikawa R et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24: 102-105.
9. Bonvalot S, Eldeweny H, Haddad V et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34: 462-468.
10. Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25: 1785-1791.
11. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-3825.
12. Maki RG, Awan RA, Dixon RH et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100: 623-626.
13. Blay JY, El Sayadi H, Thiesse P et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumour (PVNS/TGCT). Ann Oncol 2008; 19: 821-822.
14. Mace J, Sybil BJ, Sondak V et al. Response to extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95: 2373-2379.
15. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24: 1195-1203.
16. Heinrich MC, Joensuu H, Demetri GD et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008; 14: 2717-2725.
17. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205-216.
18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
21. Penel N, Blay JY, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 2008; 358: 2746-2747.
22. Mitchell G, Thomas JM, Harmer CL. Aggressive fibromatosis: evidence for a stable phase. Sarcoma 1988; 2: 149-154.
23. Micke O, Seegenschmiedt MH, German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study. Int J Radiat Oncol Biol Phys 2005; 61: 882-891.
24. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002; [347:] 472-480.
25. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25: 110-613.
26. Simon R. A roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23: 7332-7341.